first BNCT Phase II clinical trial patient treatment at Petten [FW]

["Franta, Jaroslav" <frantaj@AECL.CA>]

 FYI......

 

-----Original Message-----

From: Andrea Wittig [mailto:andrea.wittig@UNI-ESSEN.DE]

Sent: Thursday, July 15, 2004 11:36 AM

To: BNCT@MITVMA.MIT.EDU

Subject: first patient treatment within EORTC trial 11011



Last week, the first patient in a new Phase II clinical trial (EORTC

Protocol 11011) received BNCT at the European Commission's High Flux Reactor

at Petten in the Netherlands. The patient was suffering from brain

metastases of malignant melanoma, and received the boron compound BPA. The

treatment went well and according to the protocol. 

This was also the first time for such a patient to be treated in Europe. The

trial is realized within a research project  financed via the 5th Framework

Programme of the European Commission and coordinated by Dr. Wolfgang

Sauerwein. Approximately 4 years of preparation were necessary to prepare

the trial including all legal 

and regulatory aspects. Partners in the project are:

- University of Essen (Germany)

- Joint Research Center of the European Commission Petten (The Netherlands)

- European Organization for Research and Treatment of Cancer (EORTC)

(Belgium)

- NRG Petten (The Netherlands)

- Free University Amsterdam (The Netherlands)

- University of Reims (France)

- University of Münster (Germany)

- University of Frankfurt (Germany)

- University of Bonn (Germany)

- University of Kaposvar (Hungary)

- KATCHEM (Czech Republic)



Associated partners supporting the project in a lot of aspects are:

- Foundation Neurochirugie 2001 Lausanne (Switzerland)

- University of Nice and Centre Antoine-Lacassagne Nice (France)

- CNR - ITB Segrate (MI) (Italy)

- Max Planck Institute Dortmund (Germany) 



The protocol EORTC 11011 was written in a joined effort together with the

colleagues from the MIT/Harvard BNCT Group.



I would like to take this opportunity to thank all participating colleagues

for the excellent and enthusiastic collaboration over the last years, which

made this possible.



Dr. Andrea Wittig

Study Coordinator (EORTC Protocol 11011)